These press releases are intended as reference information for investors and journalists. The information contained in each press release was current at the time of issuance, and KCI assumes no responsibility for updating the information to reflect subsequent developments.
Nanova™ Therapy System Now Available from Acelity
Device Combines Absorbent Dressing with Negative Pressure Facilitates Earlier Patient Discharge
New Study Comparing ABThera™ to BVPT, Published in the Annals of Surgery, Demonstrated Reduced 90-Day Mortality
Acelity L.P. Inc. Reports Fourth Quarter and Full Year Financial Results for 2014
- Fourth quarter revenue grew 6.5% compared to the prior-year period, on a constant currency basis
- Fourth quarter 2014 Adjusted EBITDAfrom continuing operations1 grew 5.4% compared to the prior-year period, on a constant currency basis
- Fourth quarter loss from continuing operations was $30.9 million compared to $52.0 million for the prioryear period